Nasdaq Hits Record High as Amazon Leads Tech to Glory
Investing.com
Published Jul 20, 2020 03:53PM ET
Updated Jul 20, 2020 04:05PM ET
By Yasin Ebrahim
Investing.com – The Nasdaq closed at record highs on Monday as investors piled into tech stocks ahead of several quarterly earnings for mega-cap tech companies slated for later this week.
The S&P 500 gained 0.85%, while the Nasdaq Composite added 2.5% and the Dow Jones Industrial Average rose 0.03%.
Tech made a bold start to the week, led by Apple (NASDAQ:AAPL), Microsoft (NASDAQ:MSFT), Alphabet (NASDAQ:GOOGL) and Amazon.com (NASDAQ:AMZN), the so-called Fab 5, making up about 40% of the Nasdaq Index as Wall Street served up bullish upgrades on the sector.
Amazon surged 7.9% after Jefferies (NYSE:JEF) upgraded its price target on the stock to $3,800 from $3,100, citing an acceleration in online spending this year. Google, meanwhile, rose 3.3% after Credit Suisse analyst Stephen Ju hiked the price target on Alphabet to $1,850 from $1,600 ahead of its second-quarter results due July 30.
Tesla (NASDAQ:TSLA) was also a big contributor to the heavy-weight index, racking up gains of 9.5%.
Beyond big tech, the vaccine race continues to heat up, with AstraZeneca (NYSE:AZN) and Oxford University revealing a positive update on a potential Covid-19 candidate.
The phase 1 trial, which included 1,000 patients, showed that doses of the vaccine – called ChAdOx1 nCov-19 - triggered an immune response in patients, boosting their antibodies and white blood cells to fight the virus.
"The immune responses observed following vaccination are in line with what we expect will be associated with protection against the SARS-CoV-2 virus, although we must continue with our rigorous clinical trial program to confirm this," said Andrew Pollard, chief investigator of the Oxford Vaccine Trial. "We saw the strongest immune response in participants who received two doses of the vaccine, indicating that this might be a good strategy for vaccination."
Other companies in the race for the vaccine fell. Moderna (NASDAQ:MRNA) was down nearly 13% after JPMorgan (NYSE:JPM) downgraded the company to neutral from overweight, though it raised its price target on the stock to $89 from $60.
As U.S. Covid-19 cases topped 3.5 million, investors reined in their bets on stocks tied to a smooth reopening of businesses amid fears further shut downs loom.
American Airlines (NASDAQ:AAL) fell 3.7%, Marriott International (NASDAQ:MAR) slid 3.3%, Carnival (NYSE:CCL) slipped 3%, and Wynn Resorts (NASDAQ:WYNN) was down 3.4%.
In deal news, Chevron (NYSE:CVX), down 2.2%, tabled an offer to buy Noble Energy (NASDAQ:NBL) for $5 billion.
Get The News You Want
Written By: Investing.com
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.